Flow Cytometry Molecular Biology

Deepal Pandya

**** ****** ****** *****, *******, CA 94539

510-***-**** *************@*****.***

LinkedIn

Professional Summary

Biotechnology expert with over 17 years of experience in antibody engineering and antibody discovery. Skilled in Surface plasmon resonance/SPR(Carterra), Bio layer Interferometry/BLI(Octet), molecular biology, ELISA, qPCR, mammalian cell culture, cell-based assays (cytokine release, T-cell activation, ADCC, CDC, reporter cell assay, etc), SDS-PAGE, Western blot, Flow cytometry, protein modeling (MOE & BioLuminate), and purification (AKTA). Proven project leader with multiple patents and publications, Method development and optimization. Excellent oral and written communication skills, critical thinking and project leadership. Experience

IGM Biosciences, CA

Senior Scientist Antibody Engineering, March 2025 – May 2025 Scientist III Jan 2024-March 2025

• Project lead IgM-based agonist T-cell engager projects; principal inventor on patent WO 2024/148336 A1.

• Developed affinity detuning, and half-life extension constructs for PK testing. Characterization of humanized and antibody campaign antibodies by BLI/SPR, ligand competition assay.

• Characterization of developability mitigation antibody variants by BLI.

• Mentored junior scientists and served as SME for SPR & BLI assays, pH-dependent FcRn binding flow cytometry assays, ELISA & SPR.

Scientist II, Aug 2022 - Jan 2024

• Designed and characterized fusion proteins and bi and multi specific T-cell engager (CD3,CD28,4-1BB) antibodies.

• SME for BLI-based analytics for developability & liability mitigation variants. Scientist I, Aug 2021 - Aug 2022

• Contributed to projects on antibody kinetics and structural analysis.

• Characterized T-cell engager agonists for the lead optimization by several functional cell-based assays (T-cell activation reporter assay, CDC, ADCC, Cytokine release assay). Associate Scientist, Aug 2019 - Aug 2021

• COVID-19 antibody projects resulting in US patents US-202********-A1, US-202********-A1; co-authored a paper Nature "Nasal delivery of an IgM offers broad protection against SARS-CoV-2 variants" (Nature, June 3, 2021)

Ohlone College, Fremont, CA

Adjunct Faculty, Biotechnology, June 2014 - June 2019

• Taught immunology, Molecular cell biology and cell culture, enhancing students' biotech industry readiness. • Awarded ‘Faculty of the Year’ in 2018.

Celltheon, Hayward, CA

Director R&D, Jan 2012 - June 2014

• Established a new company and completed CRO projects on antibody expression and bioassays. Oxford BioTherapeutics, San Jose, CA

Scientist/Team Leader, Jan 2011 - Jan 2012

• Managed antibody engineering & cell line development projects for preclinical studies. Élan Pharmaceuticals, South San Francisco, CA

Associate Scientist, Apr 2006 - Aug 2010

• Led antibody humanization and cytokine release assays.

• Isolation of target genes from animal model tissues and analysis using RT-PCR. Protein Design Labs Inc., Fremont, CA

Senior Research Associate, June 2001 - May 2005

• Conducted several antibody engineering and humanization projects and trained interns. Education

• MSc, Biological Sciences, San Jose State University, CA, USA

• BSc, Microbiology, Bombay University, India

Skills

• Antibody kinetics & epitope binning expert

• Protein engineering and expression

• Cell culture, cell-based assays and molecular biology

• Bioinformatics tools: BioLuminate & MOE

• Strong communication and leadership

Awards and Accomplishments

• Inventor on multiple patents related to antibody engineering

• Published in Nature for SARS-CoV-2 antibody research

• Recipient of ‘Faculty of the Year’ award, 2018

• Poster contribution & presentations:

“Novel CD123xCD3 Bispecific IgM Antibody, IGM-2537, Potently Induces T-cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells in Vivo and in Vitro with Minimal Cytokine Release.” IGM Biosciences, Inc., Mountain View, CA. ASH, December 9-12, 2023

“Co-stimulatory IgM T-cell Engagers with Enhanced and Durable Cytotoxicity”. IGM Biosciences, Inc., Mountain View, CA. SITC, San Diego, November 1-5, 2023.o-

“Generation of high affinity Humanized anti-IP-10 monoclonal antibody by protein engineering.” Protein Design Labs, Inc. Asilomar Immunology conference, 2005.

• Completed online Schrodinger’s course on “Introduction to Molecular Modeling in Drug Discovery” and

“Molecular Modeling for Antibody Engineering”. June 2022

• Completed on-site Advanced SPR Carterra training, October 2023

• Recipient of ‘Faculty of the Year’ award, Ohlone College, 2018.

Contact this candidate